Literature DB >> 17111129

CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.

Alexandra Winkler1, Richard Zigeuner, Peter Rehak, Georg Hutterer, Thomas Chromecki, Cord Langner.   

Abstract

Expression of the mucin-like adhesion molecule CD24 has been implicated in the progression of several types of cancer and has been identified as new prognostic factor. We evaluated CD24 expression in 268 consecutive cases of upper urinary tract urothelial carcinoma with respect to associations with tumour stage, grade, angioinvasion and infiltrative growth pattern using a tissue microarray technique and correlated data with patient outcome. CD24 expression was demonstrated in 161/259 (62%) evaluable tumours and was associated with high tumour stage [77/139 (55%) pTa/pT1 vs 84/120 (70%) pT2-pT4; P=0.02] and high tumour grade [68/139 (49%) low vs 93/120 (78%) high grade; P<0.001] as well as presence of angioinvasion (P=0.002) and infiltrative pattern of invasion (P=0.007). Patients with CD24-positive tumours tended to have a higher risk of disease progression (P=0.065). Multivariate analysis, however, proved pT stage >1 [P<0.001, risk ratio (RR)=5.87, 95% confidence interval (CI)=2.88-11.95] and high tumour grade (P<0.001, RR=3.30, 95% CI 1.75-6.22) as only independent predictors of metastatic disease. In conclusion, CD24 expression in upper urinary tract urothelial cancer is associated with advanced tumour stage and high tumour grade as well as histopathological features indicative of aggressive tumour behaviour, but it lacks independent impact on patient outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17111129     DOI: 10.1007/s00428-006-0316-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  24 in total

1.  CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis.

Authors:  Petra Baumann; Natascha Cremers; Frans Kroese; Gertraud Orend; Ruth Chiquet-Ehrismann; Toshi Uede; Hideo Yagita; Jonathan P Sleeman
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

Review 2.  CD24 and human carcinoma: tumor biological aspects.

Authors:  S C Lim
Journal:  Biomed Pharmacother       Date:  2005-10       Impact factor: 6.529

Review 3.  Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies.

Authors:  Jeanne L Garnier; G Stevenson; N Blanc-Brunat; J L Touraine; N Milpied; V Leblond; J Y Blay
Journal:  Recent Results Cancer Res       Date:  2002

4.  The role of CD24 in various human epithelial neoplasias.

Authors:  Sung-Chul Lim; Seon-Hee Oh
Journal:  Pathol Res Pract       Date:  2005       Impact factor: 3.250

5.  CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma.

Authors:  Min-Cheng Su; Chiun Hsu; Hsin-Lien Kao; Yung-Ming Jeng
Journal:  Cancer Lett       Date:  2005-08-25       Impact factor: 8.679

6.  Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.

Authors:  Cord Langner; Gerhild Rupar; Sebastian Leibl; Georg Hutterer; Thomas Chromecki; Gerald Hoefler; Peter Rehak; Richard Zigeuner
Journal:  Virchows Arch       Date:  2005-11-29       Impact factor: 4.064

7.  Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades.

Authors:  Juliane Jacob; Joachim Bellach; Robert Grützmann; Ingo Alldinger; Christian Pilarsky; Manfred Dietel; Glen Kristiansen
Journal:  Pancreatology       Date:  2004-07-14       Impact factor: 3.996

Review 8.  Urothelial neoplasms of the kidney and ureter. An epidemiologic, pathologic, and clinical review.

Authors:  Elizabeth M Genega; Christopher R Porter
Journal:  Am J Clin Pathol       Date:  2002-06       Impact factor: 2.493

9.  CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.

Authors:  Glen Kristiansen; Christian Pilarsky; Janja Pervan; Burkhard Stürzebecher; Carsten Stephan; Klaus Jung; Stefan Loening; Andre Rosenthal; Manfred Dietel
Journal:  Prostate       Date:  2004-02-01       Impact factor: 4.104

10.  Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers.

Authors:  P Surowiak; V Materna; B Györffy; R Matkowski; A Wojnar; A Maciejczyk; P Paluchowski; P Dziegiel; M Pudełko; J Kornafel; M Dietel; G Kristiansen; M Zabel; H Lage
Journal:  Br J Cancer       Date:  2006-08-07       Impact factor: 7.640

View more
  5 in total

Review 1.  CD24: from a Hematopoietic Differentiation Antigen to a Genetic Risk Factor for Multiple Autoimmune Diseases.

Authors:  Yixin Tan; Ming Zhao; Bo Xiang; Christopher Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 2.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

3.  Clinicopathologic and prognostic significance of CD24 in gallbladder carcinoma.

Authors:  Bo Liu; Yangde Zhang; Mingmei Liao; Zhansheng Deng; Liansheng Gong; Jiarui Jiang; Ling Lynn; Kai Wu; Xiongying Miao
Journal:  Pathol Oncol Res       Date:  2010-06-22       Impact factor: 3.201

Review 4.  CD24: from A to Z.

Authors:  Xianfeng Fang; Pan Zheng; Jie Tang; Yang Liu
Journal:  Cell Mol Immunol       Date:  2010-02-15       Impact factor: 11.530

5.  Significance of ureteroscopic biopsy grade in patients with upper tract urothelial carcinoma.

Authors:  Junya Furukawa; Hideaki Miyake; Iori Sakai; Masato Fujisawa
Journal:  Curr Urol       Date:  2012-12-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.